Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Hematologic Neoplasms 10Multiple Myeloma 8Lymphoma 5Leukemia, Myeloid, Acute 5Neoplasms 4Glioma 3Thyroid Carcinoma, Anaplastic 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neurofibromatosis 1 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

Cyclophosphamide 207fludarabine phosphate 182Azacitidine 153fludarabine 141Busulfan 139Tacrolimus 118Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 105Peripheral Blood Stem Cell Transplantation 97Antilymphocyte Serum 95Melphalan 89Filgrastim 86Cyclosporine 81Methotrexate 78Decitabine 78venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 46Cord Blood Stem Cell Transplantation 43thymoglobulin 41Clofarabine 41Etoposide 35Specimen Handling 34Methylprednisolone 34Sirolimus 33Biopsy 27Injections 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × trametinib × Other hematologic neoplasm × Clear all
NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
21 enrolled 14 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡